Pharmaceutical regulation in Greece at the crossroad of change: Economic, political and constitutional considerations for a new regulatory paradigm

Health Policy

Volumn 82, Issue 1, 2007, Pages 116-129

  Contiades, Xenophon ^a   Golna, Christina ^b   Souliotis, Kyriakos ^c  

^a Centre for European Constitutional Law   (Greece)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^c NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

Author keywords

Health expenditures; Health policy; Pharmaceutical regulation; Pharmaceuticals; Pricing; Reimbursement

Indexed keywords

ARTICLE; DRUG INDUSTRY; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; GREECE; HEALTH CARE POLICY; LEGAL ASPECT; POLITICS; PROSPECTIVE PRICING; SOCIAL INSURANCE;

DRUG INDUSTRY; GOVERNMENT REGULATION; GREECE; HEALTH EXPENDITURES; HUMANS; POLITICS;

EID: 34247252906     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2006.09.003     Document Type: Article

References (37)

1. Kanavos P. The politics of health and the industrial economics of pharmaceuticals: is there a single European dimension. In: Stanyer J. (Ed). Contemporary political studies vol. 1 (1998) 74
2. Souliotis K. Analysis of health care expenditure in Greece 1989-2000. Methodological clarifications and conclusions on the Greek health care system. In: Kyriopoulos J., and Souliotis K. (Eds). Health care expenditure in Greece: methodological issues and consequences on health policy (2001), Papazisis Publications, Athens 65-78 (in Greek)
3. Golna C., Contiades X., and Souliotis K. Pharmaceutical policy in Greece and Europe, function of the market and regulatory framework (2005), Papazisis Publications, Athens (in Greek)
4. Abel-Smith B. Introduction to health policy, planning and financing (1994), Longman [chapter 14]
5. Phelps C. Health economics (1997), Addison-Wesley, Massachusetts
6. Mooney G. Key issues in health economics (1994), Harvester Wheatsheaf
7. Souliotis K., and Kyriopoulos J. Pricing policies in Greece and their effect on health care services. In: Kyriopoulos J., Liaropoulos L., Boursanidis C., and Economou C. (Eds). Health insurance in Greece (2001), Themelio, Athens 111-124 (in Greek)
8. Tountas Y. Society and health (2000), Odysseas Publications, Athens (in Greek)
9. Institute of Pharmaceutical Research and Technology (IFET), http://www.ifet.gr.
10. Kontozamanis V., and Kousoulakou H. The market for pharmaceuticals in Greece (2003), IOBE, Athens (in Greek)
11. OECD Health Data, 2003 ed.
12. Souliotis K., and Kyriopoulos J. Pricing policies in Greece and their effect on health care services. In: Kyriopoulos J., Liaropoulos L., Boursanidis C., and Economou C. (Eds). Health insurance in Greece (2001), Themelio, Athens 111-124 (in Greek)
13. Kyriopoulos J. The use of economic indicators as a tool for health policy. In: Kyriopoulos J., and Souliotis K. (Eds). Health care expenditure in Greece: methodological issues and consequences on health policy (2001), Papazisis Publications, Athens 79-88 (in Greek)
14. Kyriopoulos J. The use of economic indicators as a tool for health policy. In: Kyriopoulos J., and Souliotis K. (Eds). Health care expenditure in Greece: methodological issues, consequences on health policy (2001), Papazisis Publications, Athens 79-88 (in Greek)
15. Kontozamanis V. The market for pharmaceuticals in Greece (2001), IOBE, Athens (in Greek)
16. Souliotis K., and Kyriopoulos J. Pricing policies in Greece and their effect on health care services. In: Kyriopoulos J., Liaropoulos L., Boursanidis C., and Economou C. (Eds). Health insurance in Greece (2001), Themelio, Athens 111-124 (in Greek)
17. Kanavos P., and Golna C. Pharmaceutical regulation in Europe: industry challenges (2000), Informa Pharmaceutical Publications, London
18. Hellenic Association of Pharmaceutical Companies (SFEE), The pharmaceutical market in Greece: facts and figures, 2003, http://www.sfee.gr.
19. Papadopoulou-Daifoti S. The battle for the positive list: the state's intentions, the experts' contradicting views and the financial bleeding of the social security funds. Oikonomikos Taxydromos F 13 2603 (2004) 9-26 (in Greek)
20. Kanavos P. Pharmaceutical pricing and reimbursement in Europe. 1999 ed (1999), PJB Publications, Surrey, UK
21. Papadopoulou-Daifoti S. The battle for the positive list: the state's intentions, the experts' contradicting views and the financial bleeding of the social security funds. Oikonomikos Taxydromos F 13 2603 (2004) 9-12 (in Greek)
22. Liaropoulos L. The present and future of pharmaceuticals in Greece. In: Geitona M., and Kyriopoulos J. (Eds). Politics and economics of pharmaceutical care in Greece (1999), Themelio, Athens (in Greek)
23. Hellenic Association of Pharmaceutical Companies (SFEE), The pharmaceutical market in Greece: facts and figures, 2003, http://www.sfee.gr.
24. Ranos C. The battle for the positive list: the state's intentions, the experts' contradicting views and the financial bleeding of the social security funds. Oikonomikos Taxydromos F 13 2603 (2004) 9-12 (in Greek)
25. Golna C., Contiades X., and Souliotis K. Pharmaceutical policy in Greece and Europe, function of the market and regulatory framework (2005), Papazisis Publications, Athens (in Greek)
26. Contiades X. Constitutional guarantees and institutional organisation of the social security system. Ant Sakkoulas Athens-Komotini (2004)
27. Contiades X. Issues of constitutionality of the regulation of the pricing of medicinal products. Revue Hellénique des Droits de l' Homme, Ant Sakkoulas Bruylant 25 (2005) 149-167
28. Golna C., Contiades X., and Souliotis K. Pharmaceutical policy in Greece and Europe, function of the market and regulatory framework (2005), Papazisis Publications, Athens (in Greek)
29. Ministry of Health and Social Solidarity. Position paper on a new pharmaceutical policy (2004), Ministry of Health and Social Solidarity, Athens
30. In: Mossialos E., Mrazek M., and Walley T. (Eds). Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality, World Health Organisation on behalf of the European Observatory on Health Care Systems (2004), Open University Press, Berkshire
31. Golna C., Contiades X., and Souliotis K. Pharmaceutical policy in Greece and Europe, function of the market and regulatory framework (2005), Papazisis Publications, Athens (in Greek)
32. Golna C., Contiades X., and Souliotis K. Pharmaceutical policy in Greece and Europe, function of the market and regulatory framework (2005), Papazisis Publications, Athens (in Greek)
33. Golna C., Contiades X., and Souliotis K. Pharmaceutical policy in Greece and Europe, function of the market and regulatory framework (2005), Papazisis Publications, Athens (in Greek)
34. Audit Commission. A prescription for improvement: towards more rational prescribing in general practice (1994), HMSO, London
35. Department of Health, Doctors to get latest medical advise at the touch of a button, 1998, http://www.dh.gov.uk/PublicationsAndStatistics/PressReleases/PressReleasesNotices/fs/en?CONTENT_ID=4025065&chk=o7rxcm.
36. Souliotis K., and Lionis C. Creating an integrated health care system: a primary care perspective. Journal of Medical Systems 18 6 (2004)
37. SFEE. Positions and propositions of the ministry of health and social solidarity regarding the new pharmaceutical policy (2004), Hellenic Association of Pharmaceutical Companies